Phase Ib dose finding study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL) - Regional Cancer Care Associates LLC

Clinical Trials

Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
HackensackUMC
Protocol Number
RV-CL-MCL-PI-00397
Cancer Diagnosis
To Learn More Call
201-510-0910